Technical guidance on the Introduction of HPV vaccines in European Union countries – an update
In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.
Expert opinion on the Introduction of HPV Vaccines in EU Countries
This guidance report lays down the scientific basis for the potential introduction of human papillomavirus (HPV) vaccines in order to help EU Member States to make policy choices
Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: A cervical cancer screening based studyArchived
Similar to other European countries, cervical infection with HPV-16, the HPV type with the strongest oncogenic potential, were most common both overall and among women with cervical disease.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
ECDC guidance on HPV vaccination: Focus on reaching all girlsArchived
Today, ECDC publishes an update to its 2008 Guidance on human papillomavirus (HPV) vaccines in Europe. The update follows the introduction of vaccination programmes in 19 European countries and new evidence from research studies over the past four years.
Public consultation on HPV vaccines guidance opens
This guidance covers the following areas in relation to HPV vaccination: efficacy of the nine-valent HPV vaccine, HPV vaccination in people living with HIV and HPV vaccination in males and the cost-effectiveness of extending the HPV vaccination programme to include males.